Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00309634 | Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years | PHASE1 | COMPLETED | 400 | — | — | Mar 27, 2006 | Oct 28, 2006 | May 10, 2017 | 1 | Belgium |
| Name | Type | Description |
|---|---|---|
| 4 adjuvanted pandemic influenza candidate vaccines | BIOLOGICAL | - |
| 4 non-adjuvanted pandemic influenza candidate vaccines | BIOLOGICAL | - |
Inclusion criteria: * A male or female between, and including, 18 and 60 years of age at the time of the first vaccination. * Healthy subjects as established by medical history and clinical examination before entering into the study. * If the subject is female, she must be of non-childbearing poten...